<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470495</url>
  </required_header>
  <id_info>
    <org_study_id>swhb005</org_study_id>
    <nct_id>NCT01470495</nct_id>
  </id_info>
  <brief_title>Combined Treatment of RFA and Sorafenib on Recurrent HCC</brief_title>
  <acronym>REPEAT</acronym>
  <official_title>Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Sichuan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huaxi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a
      promising drug to treat late stage HCC. But few studies were related with its effectiveness
      on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might
      reduce the frequency of recurrence and improve the overall survival and disease free survial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time interval between new lessions emerging after the first HCC recurrence</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year overrall survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>HCC</condition>
  <condition>Radiofrequency Ablation</condition>
  <condition>Sorafenib</condition>
  <arm_group>
    <arm_group_label>RFA+Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>to treat recurrent HCC both with RFA and Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To treat recurrent HCC with RFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RFA + Sorafenib</intervention_name>
    <description>combined RFA and Sorafenib to treat recurrent HCC</description>
    <arm_group_label>RFA+Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RFA</intervention_name>
    <description>treat Recurrent HCC with RFA</description>
    <arm_group_label>RFA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent HCC after curative resection

          -  without gender restriction

          -  age between 18 to 75 years

          -  The liver function showed no worse than Child-Pugh B

          -  tumor nodes were less than 5cm and no more than 3 nodules

        Exclusion Criteria:

          -  Pregnancy patients

          -  With extrahepatic tumor or lymphnode metastasis

          -  Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuansheng Ma, MD,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hopstial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaobin Feng, MD</last_name>
    <phone>+86-2368765297</phone>
    <email>fengxiaobin200708@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of hepatobiliary surgery,southwest hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>feng xiaobin, MD</last_name>
      <phone>+86-23-13228683243</phone>
      <email>fengxiaobin200708@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>feng xiaobin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>feng xiaobin</investigator_full_name>
    <investigator_title>Institute of hepatobiliary surgery,southwest hospital</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

